Second Sight preps $25M offering; Svelte Medical Systems proceeds with stent trial;

 @FierceMedDev: In case you missed it... The top medical device venture capital investments of 2012. Special Report | Follow @FierceMedDev

 @MarkHFierce: This just in: Boston Scientific's CEO says the medical device tax, in part, is forcing up to 1,000 more layoffs. Article | Follow @MarkHFierce

 @DamianFierce: Medtronic ups the ante in China, buying a $66.2M stake in a Shenzhen cardiovascular biz. More | Follow @DamianFierce

> Svelte Medical Systems treated its first patient in the DIRECT II clinical study in Belgium, a trial that will compare the company's drug-eluting coronary stent integrated delivery system with Medtronic's ($MDT) Resolute Integrity drug-eluting stent. Release

> Second Sight Medical is prepping a $25 million offering involving equity, debt, options and warrants. Story

> Researchers in New Jersey are pursuing development of a blood test that could detect mild cognitive impairment caused by early-stage Alzheimer's disease. Item

> Providers should limit the use of FDA-approved imaging technologies to identify beta-amyloid proteins in the brain to a small group of patients, according to new joint guidelines from the Alzheimer's Association and the Society for Nuclear Medicine and Molecular Imaging. Story

> Students in a particular class at the Massachusetts Institute of Technology are focused on developing new medical devices. Story

> General Electric ($GE) is developing a robot-enabled system that would handle packaging, delivery and sterilization of surgical tools. Release

Biotech News

 @FierceBiotech: From FierceBiotechIT.com: Cypher Genomics chief speaks out from DNA data-crunching crowd. News | Follow @FierceBiotech

@JohnCFierce: Are we in for a string of winning biotech IPOs? Been a long time: First biotech IPO of '13 jumps in encouraging debut. More | Follow @JohnCFierce

@RyanMFierce: Is Pfizer stronger long-term without generics or just temporarily satisfying Wall Street? Report | Follow @RyanMFierce

> FDA staffers frown over Pharmaxis data for inhaled CF treatment. Article

> Boehringer gets FDA panel's thumbs up on 'modest' new COPD treatment. News

> FDA hands Sanofi, Isis an approval for HoFH drug Kynamro. Story

Pharma News

@FiercePharma: Vertex numbers suffer from Incivek sales swoon. Hep C drug down 51%. Whoa. Fewer new pts. More | Follow @FiercePharma

 @AlisonBFierce: Life established an international flu network to up the speed and efficiency of flu monitoring and vaccine development. Release | Follow @AlisonBFierce

@EricPFierce: The world's largest OTC plant gets under way. More | Follow @EricPFierce

> France yanking Bayer's Diane-35 off the market. Article

> Pfizer may split, CEO says, but don't expect a decision soon. Story

Drug Delivery News

> Sanofi launches 'talking' emergency epinephrine injector. Report

> Sustained-release contact lenses deliver eye drugs postsurgery. Article

> DNA vaccine tattoo triggers HIV immune response. News

> MIT researchers deliver to cells with a squeeze. Story

> Tunable jelly takes ups and downs out of peptide delivery. Item

Suggested Articles

Synthetic DNA weaver Twist Bioscience announced a handful of new collaborations this week amidst a $140 million raise from an underwritten offering.

The FDA has announced a series of actions aimed at limiting the use of power morcellators in gynecologic surgeries.

J&J launched a virtual clinical study to gauge whether Apple’s iPhone and ECG-enabled smartwatch can help reduce the risk of stroke and catch AFib.